In partnership with
Invest in Popsmith, the Future of Popcorn
Popsmith is reimagining popcorn for a new generation.
With more than 100,000 customers, $20M+ in lifetime revenue, and retail partnerships with Williams Sonoma, Costco, and Sur La Table, Popsmith is building a premium brand in one of America’s most iconic snack categories.
Revenue is projected to reach $9M in 2026, with a nationwide Williams Sonoma rollout coming this holiday season.
Now, for a limited time, you can own a piece of the company and participate in what comes next.
See the Popsmith investment opportunity.
Kodiak Sciences
Ticker: KOD
Exchange: Nasdaq
Sector: Biotechnology
Focus: Retina diseases and ophthalmic medicines
Kodiak Sciences is the small-cap stock drawing major attention today after reporting positive Phase 3 results for its DAYBREAK study. The company said both Zenkuda and tabirafusp-ted met their primary endpoints in patients with wet age-related macular degeneration, or wet AMD.
The catalyst behind the move
Kodiak’s DAYBREAK trial compared its therapies with aflibercept, an established wet-AMD treatment. According to the company, both candidates achieved non-inferior vision improvements after one year.
The most eye-catching result involved Zenkuda: Kodiak said 54% of patients achieved six-month dosing durability at one year, while the study used strict retreatment criteria designed to reflect real-world treatment practices.
That matters because wet-AMD patients often require repeated eye injections. A treatment that can maintain vision with fewer injections could be commercially attractive for patients, physicians, and healthcare providers.
Why investors are watching KOD
Kodiak is a precommercial biotechnology company, meaning it does not yet have an established commercial product generating recurring sales. The company’s investment case therefore rests heavily on clinical results, regulatory progress, future partnerships, and the possibility of eventual product approval.
The DAYBREAK data could improve Kodiak’s position in the competitive retina-drug market and potentially support future regulatory filings. The company announced the results through its investor-relations channel on September 28, making the report the central near-term catalyst for the stock.
Trading activity has also increased substantially. Yahoo Finance reported approximately 2.28 million shares traded, versus average volume of roughly 701,000 shares.
Market sentiment
Market sentiment is strongly positive but highly speculative.
The immediate reaction has been bullish because both drug candidates met their primary endpoints.
Analyst coverage before the data leaned positive: MarketBeat reported a Moderate Buy consensus, with six Buy ratings, one Hold, and one Sell.
Reported price targets varied widely, with estimates ranging from approximately $36 to $80, highlighting both optimism and uncertainty.
HC Wainwright reiterated a Buy rating and assigned a $58 target before the data release.
The wide range of targets is important. Investors appear excited about Kodiak’s clinical progress, but analysts still disagree about how much commercial value should be assigned to the pipeline. Positive trial data does not automatically guarantee regulatory approval, successful commercialization, or long-term shareholder returns.
What could go right
Kodiak’s bullish case depends on several developments:
Regulators accept the DAYBREAK data and allow the company to advance toward approval.
Zenkuda’s dosing durability translates into a meaningful competitive advantage.
Physicians and patients value fewer injections without sacrificing vision outcomes.
Kodiak secures a partner with the financial and commercial resources to launch the treatments.
Additional clinical data confirm the DAYBREAK results.
What could go wrong
The stock also carries significant risks:
Phase 3 success does not eliminate regulatory or manufacturing risk.
The company has no established commercial revenue base.
Competing retina treatments may offer similar efficacy or dosing convenience.
A sharp run-up can create a “buy the rumor, sell the news” reaction even after positive results.
Further financing could dilute existing shareholders if Kodiak needs more capital.
Investor takeaway
Kodiak Sciences is one of the more event-driven small-cap stocks in the U.S. market today. The positive DAYBREAK results materially improve the story around Zenkuda and tabirafusp-ted, and the market’s initial reaction and analyst coverage suggest optimism about Kodiak’s future.
However, small-cap stocks are volatile, and investors should use caution when investing in a small-cap stock. Biotechnology stocks can move dramatically on clinical, regulatory, financing, or partnership news. KOD should be viewed as a speculative event-driven position—not as a low-risk substitute for a diversified healthcare or biotechnology fund.
This newsletter is for informational purposes only and is not personalized investment advice.
The agentic era needs a different CRM. That’s Attio.
Parallel, Turbopuffer, and Wordsmith run their entire GTM motion on Attio, with agents that chase every buying signal, build pipeline, and move deals forward, 24/7.
Read more here
Until next week, keep compounding …
Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, or trading advice. Investing in securities involves risk, including the potential loss of principal; always conduct your own research and consult a qualified financial professional before making investment decisions.
